Bolt Biotherapeutics IncNASDAQ:BOLTNASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)
- LAST PRICE0.7500
- TODAY'S CHANGE (%)0.0140 (1.9022%)
- Bid / Lots0.7260/ 13
- Ask / Lots0.7699/ 228
- Open / Previous Close0.7400 / 0.7360
- Day Range
- 52 Week Range
- Volume138,257
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | BOLT |
|---|---|---|
| 09:45 ET | 1500 | 0.74 |
| 09:57 ET | 2000 | 0.7401 |
| 10:10 ET | 2000 | 0.74055 |
| 10:26 ET | 600 | 0.7409 |
| 10:28 ET | 400 | 0.7454 |
| 10:50 ET | 337 | 0.7409 |
| 10:57 ET | 450 | 0.7411 |
| 11:04 ET | 182 | 0.741 |
| 11:45 ET | 2500 | 0.744499 |
| 11:47 ET | 5000 | 0.7433 |
| 11:49 ET | 5925 | 0.7445 |
| 11:51 ET | 100 | 0.7408 |
| 11:58 ET | 288 | 0.7401 |
| 12:45 ET | 4000 | 0.7439 |
| 12:50 ET | 1295 | 0.7401 |
| 12:56 ET | 1324 | 0.7401 |
| 01:14 ET | 2700 | 0.736 |
| 01:15 ET | 3101 | 0.744 |
| 01:17 ET | 100 | 0.74 |
| 01:19 ET | 100 | 0.74 |
| 01:48 ET | 200 | 0.7421 |
| 02:00 ET | 2397 | 0.744 |
| 02:02 ET | 200 | 0.7421 |
| 02:22 ET | 9999 | 0.744 |
| 02:24 ET | 51970 | 0.7522 |
| 02:26 ET | 16351 | 0.7499 |
| 02:27 ET | 6800 | 0.7521 |
| 02:29 ET | 3400 | 0.757899 |
| 02:38 ET | 100 | 0.7577 |
| 02:40 ET | 435 | 0.755 |
| 02:42 ET | 5400 | 0.7502 |
| 02:51 ET | 122 | 0.7511 |
| 02:56 ET | 100 | 0.7501 |
| 02:58 ET | 1500 | 0.7501 |
| 03:25 ET | 300 | 0.7578 |
| 03:39 ET | 892 | 0.7348 |
| 03:57 ET | 812 | 0.749 |
| 03:59 ET | 100 | 0.75 |
Today
ROSEN, LEADING INVESTOR COUNSEL, Encourages Bolt Biotherapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - BOLT, from 1 hour ago by Dow Jones
1 hour ago by Dow JonesBOLT Investors Can Lead Bolt Biotherapeutics Inc Securities Fraud Lawsuit With The Schall Law Firm, from 5 hours ago by Dow Jones
5 hours ago by Dow JonesBOLT INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Bolt Biotherapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!, from 6 hours ago by Dow Jones
6 hours ago by Dow JonesSHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Bolt, from 8 hours ago by Dow Jones
8 hours ago by Dow JonesSHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Bolt Biotherapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines -- BOLT, from 8 hours ago by Dow Jones
8 hours ago by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Bolt Biotherapeutics Inc | 28.1M | -0.5x | --- |
Correlate Energy Corp | 16.8M | -1.1x | --- |
VBI Vaccines Inc | 15.5M | -0.1x | --- |
Aspira Women's Health Inc | 18.7M | -1.1x | --- |
Tonix Pharmaceuticals Holding Corp | 10.1M | 0.0x | --- |
Evogene Ltd | 24.5M | -1.1x | --- |
Company Information
Bolt Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer. The Company's pipeline candidates are built on its expertise in myeloid biology and cancer drug development. Its pipeline includes trastuzumab imbotolimod (formerly BDC-1001), a human epidermal growth factor receptor 2 - targeting Boltbody Immune-Stimulating Antibody Conjugate (ISAC), BDC-3042, a myeloid-modulating antibody, and multiple Boltbody ISAC collaboration programs. Trastuzumab imbotolimod is in Phase 2 clinical. BDC-3042, an agonist antibody targeting Dectin-2, is in a Phase 1 dose-escalation trial. In preclinical development, BDC-3042 demonstrated the ability to convert tumor-supportive macrophages to tumor-destructive macrophages. It developed a lead agonist antibody that binds to Dectin-2 and activates human tumor-associated macrophages. It is developing multiple Boltbody ISACs in strategic collaborations with biopharmaceutical companies.
Contact Information
- Headquarters
- 900 Chesapeake DriveREDWOOD CITY, CA, United States 94063
- Phone
- 650-665-9295
- Fax
- 302-531-3150
Executives
- President, Chief Executive Officer, Chief Financial Officer, Director
- William Quinn
- Chief Operating Officer
- Grant Yonehiro
- Independent Director
- James Healy
- Independent Director
- Laura Berner
- Independent Director
- Kathleen Laporte
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $28.1M |
|---|---|
Revenue (TTM) | $11.3M |
Shares Outstanding | 38.1M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.92 |
EPS | $-1.66 |
Book Value | $2.96 |
P/E Ratio | -0.5x |
Price/Sales (TTM) | 2.5 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -619.90% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
